The stock of Seelos Therapeutics Inc (NASDAQ: SEEL) has decreased by -11.67 when compared to last closing price of 0.44.Despite this, the company has seen a loss of -22.04% in its stock price over the last five trading days. InvestorPlace reported 2024-01-09 that Though psychedelic therapies and related psychedelic stocks have fallen out of favor recently, there’s still tremendous research and insight happening beneath the surface. Even Elon Musk uses ketamine as a depression therapeutic.
Is It Worth Investing in Seelos Therapeutics Inc (NASDAQ: SEEL) Right Now?
Moreover, the 36-month beta value for SEEL is 1.94. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SEEL is 12.49M and currently, short sellers hold a 5.82% of that float. On April 17, 2024, SEEL’s average trading volume was 426.30K shares.
SEEL’s Market Performance
The stock of Seelos Therapeutics Inc (SEEL) has seen a -22.04% decrease in the past week, with a -61.39% drop in the past month, and a -71.05% fall in the past quarter. The volatility ratio for the week is 14.79%, and the volatility levels for the past 30 days are at 18.46% for SEEL. The simple moving average for the past 20 days is -30.30% for SEEL’s stock, with a -96.91% simple moving average for the past 200 days.
Analysts’ Opinion of SEEL
Many brokerage firms have already submitted their reports for SEEL stocks, with ROTH Capital repeating the rating for SEEL by listing it as a “Buy.” The predicted price for SEEL in the upcoming period, according to ROTH Capital is $8 based on the research report published on September 27, 2021 of the previous year 2021.
Guggenheim, on the other hand, stated in their research note that they expect to see SEEL reach a price target of $8. The rating they have provided for SEEL stocks is “Buy” according to the report published on July 01st, 2021.
Cantor Fitzgerald gave a rating of “Overweight” to SEEL, setting the target price at $10 in the report published on June 01st of the previous year.
SEEL Trading at -52.05% from the 50-Day Moving Average
After a stumble in the market that brought SEEL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.23% of loss for the given period.
Volatility was left at 18.46%, however, over the last 30 days, the volatility rate increased by 14.79%, as shares sank -58.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -55.74% lower at present.
During the last 5 trading sessions, SEEL fell by -22.04%, which changed the moving average for the period of 200-days by -98.94% in comparison to the 20-day moving average, which settled at $0.5259. In addition, Seelos Therapeutics Inc saw -72.29% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SEEL starting from Mehra Raj, who purchase 75,757 shares at the price of $1.32 back on Dec 01 ’23. After this action, Mehra Raj now owns 185,142 shares of Seelos Therapeutics Inc, valued at $99,999 using the latest closing price.
Golembiewski Michael Joseph, the Chief Financial Officer of Seelos Therapeutics Inc, purchase 83,000 shares at $1.21 during a trade that took place back on Nov 30 ’23, which means that Golembiewski Michael Joseph is holding 86,450 shares at $100,222 based on the most recent closing price.
Stock Fundamentals for SEEL
Current profitability levels for the company are sitting at:
- -18.38 for the present operating margin
- 0.97 for the gross margin
The net margin for Seelos Therapeutics Inc stands at -18.93. The total capital return value is set at 1.21. Equity return is now at value -584.20, with -269.01 for asset returns.
Based on Seelos Therapeutics Inc (SEEL), the company’s capital structure generated -0.74 points at debt to capital in total, while cash flow to debt ratio is standing at -1.68. The debt to equity ratio resting at -0.42. The interest coverage ratio of the stock is 4499.89.
Currently, EBITDA for the company is -40.44 million with net debt to EBITDA at -0.28. When we switch over and look at the enterprise to sales, we see a ratio of 7.49. The receivables turnover for the company is 2.89for trailing twelve months and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.14.
Conclusion
To wrap up, the performance of Seelos Therapeutics Inc (SEEL) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
